| GC | PE | |
| (n = 121) | (n = 120) | |
| Age (years) | ||
| ⩽70 | 92 (76%) | 97 (81%) |
| >70 | 29 (24%) | 23 (19%) |
| Median | 62 | 62.5 |
| Range | 37–80 | 27–81 |
| Sex | ||
| Male | 68 (56%) | 68 (57%) |
| Female | 53 (44%) | 52 (43%) |
| ECOG performance status | ||
| 0 | 13 (11%) | 14 (12%) |
| 1 | 68 (56%) | 69 (58%) |
| 2 | 30 (25%) | 30 (25%) |
| 3 | 10 (8%) | 7 (6%) |
| Stage | ||
| Limited locally advanced/poor prognosis | 52 (43%) | 51 (43%) |
| Extensive | 69 (57%) | 69 (58%) |
GC, gemcitabine and carboplatin; PE, cisplatin and etoposide.